Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06939400

Enrollment

100

Registered

2025-04-22

Start date

2025-06-01

Completion date

2027-12-31

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme (GBM)

Keywords

Glioblastoma Multiforme, photodynamic therapy, metaverse, yellow fluorescence

Brief summary

GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Interventions

PROCEDUREPhotodynamic therapy (PDT)

GBM patients recevied surgical combination photodynamic therapy

PROCEDUREGBM patients recevied traditional treatment options

GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.

Exclusion criteria

* Photosensitizer allergy. * Severe coagulation disorder. * Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage. * Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties. Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.

Design outcomes

Primary

Measure	Time frame
Number of Participants with Treatment of Surgical combination Photodyanmic therapy	From June 2025 to June 2027

Countries

China

Contacts

Primary ContactShaoshan Hu, Doctor

shaoshanhu@163.com0571-85893451

Backup ContactYi Yuan, Doctor

zjsrmyykyb@163.com0571-85893451

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026